Phase II Trial of Erlotinib in Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2013

Conditions

CancerPancreas

Interventions

DRUG

Erlotinib

Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).

Trial Locations (5)

Tom Baker Cancer Centre, Calgary

Cross Cancer Institute, Edmonton

British Columbia Cancer Agency, Vancouver

CancerCare Manitoba, Winnipeg

Princess Margaret Hospital, Toronto